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Application of lanthanide luminescence in probing enzyme 
activity 
Sarah H. Hewitta and Stephen J. Butler*a
Enzymes play critical roles in the regulation of cellular function 
and are implicated in numerous disease conditions. Reliable and 
practicable assays are required to study enzyme activity, to 
facilitate the discovery of inhibitors and activators of enzymes 
related to disease. In recent years, a variety of enzymes assays 
have been devised that utilise luminescent lanthanide(III) 
complexes, taking advantage of their high detection sensitivities, 
long luminescence lifetimes, and line-like emission spectra that 
permit ratiometric and time-resolved analyses. In this Feature 
Article, we focus on recent progress in the development of 
enzyme activity assays based on lanthanide(III) luminescence, 
covering a variety of strategies including Ln(III)-labelled antibodies 
and proteins, Ln(III) ion encapsulation within defined peptide 
sequences, reactivity-based Ln(III) probes, and discrete  Ln(III) 
complexes. Emerging approaches for monitoring enzyme activity 
are discussed, including the use of anion responsive lanthanide(III) 
complexes, capable of molecular recognition and luminescence 
signalling of polyphosphate anions. 
Assays to monitor enzyme reactions are vital for 
understanding enzyme mechanism and function and for the 
discovery of novel inhibitors. Therefore, the design of robust, 
sensitive and easy-to-use enzyme assays is of great importance 
for biological and pharmaceutical researchers. The search for 
new enzyme inhibitors typically begins with high-throughput 
screening of potential lead compounds, followed by 
measurements of selectivity and potency.1,2 To conduct these 
studies, assays are required that are amenable to high-
throughput analyses, can be used in low volumes with low 
concentrations of expensive components, operate in aqueous 
buffer, and provide a readout with high signal-to-noise.3 The 
use of luminescence in enzyme assays is particularly attractive 
due to the high measurement sensitivity and rapid response 
times, permitting high-throughput analysis using standard 
well-plate techniques.4,5 In addition, the high sensitivity of 
luminescence6 allows the use of low concentrations of 
potentially costly assay components.  
Most enzyme assays operate by monitoring the accumulation 
of product or the depletion of substrate.3 This can be achieved 
in a variety of ways, including the detection of a species 
labelled with a colourimetric or luminescent tag,7,8 or the 
detection of a native substrate or product using a luminescent 
reporter molecule, typically based on an antibody or a 
synthetic receptor.4,9 Such assays can function in real-time, 
detecting the change in luminescence during the enzyme 
reaction, or can be single end-point, wherein the enzyme 
reaction is stopped prior to measurement. End-point assays 
can be valuable as the enzyme reaction can be performed in 
optimal conditions with native substrates; however, they 
require a separate enzyme reaction to be set up for each data 
point required and thus can be costly in terms of materials.10 
Figure 1. Strategies for monitoring enzyme reactions using lanthanide(III) complexes. a) 
Ln(III) Labelled antibody, b) Ln(III) ion encapsulation within a polypeptide sequence, c) 
Ln(III) labelled biomolecule, usually a peptide, d) Discrete lanthanide(III) complex. 
In recent years, several new approaches to enzyme assays 
have been devised that exploit the attractive photophysical 
properties of luminescent lanthanide(III) complexes.11 
Lanthanide-based enzyme assays may function in a number of 
ways. Firstly, reactivity-based probes have been developed, in 
which the Ln(III) complex or ligand is modified irreversibly 
during the enzyme reaction,12,13 altering its luminescence or 
chelating properties in the process. Secondly, Ln(III) ions have 
been incorporated directly into biological molecules,14–18 
either by functionalising antibodies (Figure 1a), replacing 
endogenous Ca(II) ions in protein binding domains (Figure 1b), 
conjugating Ln(III) complexes to native amino acids or 
incorporating lanthanide-chelating, non-natural amino acids 
into peptides (Figure 1c). The luminescence properties of the 
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incorporated Ln(III) ion are modulated during the enzyme 
reaction. Thirdly, discrete Ln(III) complexes (Figure 1d) may be 
used that bind reversibly to a substrate or product of the 
enzyme reaction (e.g. peptides, anions, small molecules),19 
reporting on the depletion or accumulation of these species by 
changes in emission intensity or lifetime of the Ln(III) complex. 
Herein, we discuss the applications of these different types of 
enzyme assay. 
Luminescent lanthanide(III) Complexes 
Luminescent lanthanide(III) complexes are generating 
increased interest in a range of bioanalytical studies, 
particularly those of europium(III) and terbium(III).20–22 Ln(III) 
complexes offer several advantages over conventional organic 
fluorophores for use in biological applications, including a large 
separation between absorption and emission spectra, 
minimising excitation light interference, and line-like emission 
spectra with clearly defined bands, allowing ratiometric 
analyses.11,23 Emissive Ln(III) complexes are particularly 
attractive for their long luminescence lifetimes (Figure 2a), 
which permits the use of time-gated detection techniques to 
completely remove the autofluorescence from biological 
fluorophores (e.g. tryptophan (Trp) and tyrosine (Tyr) residues 
in proteins), thereby improving signal-to-noise ratio.24–27 Time-
gated luminescence can also be used with Förster resonance 
energy transfer (FRET) technology,28–30 allowing much longer 
emission lifetimes to be observed for a conventional organic 
fluorophore, following excitation from a lanthanide donor. This 
enables time-resolved FRET to be observed for an organic 
fluorophore, which exhibits very short-lived emission in the 
absence of the Ln(III) donor. Luminescent lanthanide(III) 
complexes have found increased practical use for a range of 
biological applications,11,21,31–33 including cellular imaging, 
sensing of biologically important analytes and diagnostics. 
Figure 2. a) Long luminescence lifetime of the Ln(III) complex, compared to a 
conventional organic fluorophore, permitting time-gated luminescence measurements. 
b) Cartoon of antenna excitation. Excitation light excites the antenna, followed by 
energy transfer to the Ln(III) ion, which consequently emits light. c) Simplified Jablonski 
diagram depicting the antenna excitation for Eu(III) or Tb(III). The antenna is excited to 
its singlet state, energy is then transferred to its triplet state by intersystem crossing 
(ISC), followed by energy transfer to the lanthanide excited state, which consequently 
emit light on r to the ground state. 
Several aspects need to be considered in the design of a 
luminescent lanthanide complex. Firstly, the direct excitation 
of Ln(III) ions is very inefficient, due to the Laporte forbidden 
nature of the f-f transitions. However, highly luminescent 
lanthanide complexes can be devised by incorporating a 
strongly absorbing chromophore (or antenna) into the ligand 
design.34 A simplified photophysical pathway for sensitisation 
of Ln(III) luminescence is shown in Figure 2b and c, involving 
energy transfer from the triplet excited state of an absorbing 
antenna to the Ln(III) excited state, resulting in metal-centred 
luminescence.35 The participation of intra-ligand charge 
transfer states in the Ln(III) sensitisation process has been 
associated with antennae containing donor and acceptor 
components separated by a conjugated system.36,37 The nature 
of the sensitising group can be particularly useful in designing 
responsive lanthanide probes, as changes to the antenna can 
modulate its absorption or energy transfer properties. These 
changes can result from irreversible reaction with biological 
analytes,12 or from reversible non-covalent interactions (e.g. π-
π stacking),38 perturbing the singlet or triplet excited states of 
the antenna.  
Secondly, lanthanide ions typically adopt coordination 
numbers of between 8 and 10 in aqueous solution,39 so the 
ligand design must incorporate a sufficient number of hard 
donors to satisfy this coordination sphere. A wide range of 
kinetically stable 1:1 complexes of Ln(III) ions with 
heptadentate or octadentate ligands have been developed,40–
44 often based on carboxylic acid functionalised cyclen, 9N3 
macrocycles, or open DTPA or EDTA derivatives, but can also 
be well-defined peptide sequences.45 If the Ln(III) coordination 
sphere is not satisfied, water molecules will occupy the 
remaining coordination sites, resulting in quenching of 
luminescence due to vibrational energy transfer to O-H 
oscillators.46 The quenching effect of bound water molecules 
can be utilised in the design of responsive Ln(III) 
complexes,20,47 wherein displacement of coordinated water by 
anionic species causes an enhancement in Ln(III) emission 
intensity and pronounced changes in emission spectral form, 
arising from a change in the primary coordination sphere of 
the Ln(III) ion.38,48 Eu(III)-based probes that utilise this sensing 
mechanism can be ratiometric in nature, normally by 
observing the change in intensity of the hypersensitive 
electric-dipole transition (5D0–7F2), relative to the emission 
intensity of the magnetic-dipole transition (5D0–7F1), which is 
insensitive to changes in the coordination environment of the 
Ln(III) ion.49 Ratiometric analyses have also been achieved by 
using cocktails of lanthanide complexes, comparing bands 
from the two complexes to generate a ratiometric signal. 
Generally, this approach utilises a Ln(III) complex that is 
sensitive to the presence of a particular species, and one 
which is invariant to changes in that species.50 
Reactivity based lanthanide probes 
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Reaction of the sensitising antenna can modulate the 
luminescent properties of the lanthanide(III) complex,12 either 
by generating a chelating antenna from a non-chelating 
precursor or by changing the energy transfer properties of an 
already attached antenna.51 Many examples of the former 
approach were reported in the 1990s, the most common 
involving the generation of Ln(III) chelating salicylic acid 
derivatives via the hydrolysis of phosphoesters,13,52,53 
oxidation of aldehydes13 or hydrolysis of glycosidic 
linkages,13,52 by alkaline phosphatase, xanthine oxidase and β-
galactosidase respectively (Figure 3a). In each case, reversible 
binding of the salicylate derivative to Tb(EDTA) switches on 
Tb(III) luminescence. Other reactions monitored using the 
same approach have included horseradish peroxidase,54 
esterases,55,56 lysozyme,57,58 β-glucosidase,59 lipase,59 and 
glucose oxidase.13 This methodology has been applied in an 
immunoassay technique called enzyme-amplified lanthanide 
luminescence (EALL),60 where an antigen is recognised by an 
antibody with an enzyme attached. This enzyme catalyses the 
formation of the chelating antenna from the non-chelating 
compound, which coordinates to the Ln(III) ion, providing a 
luminescent signal. The luminescence response is thus 
dependent on initial recognition of the antigen.  
 
Figure 3. Reactivity based probes. a) Generation of a terbium(III) chelating salicylic acid-
based antennae by various different enzyme reactions on appropriate substrates, 
leading to emissive Tb(III) complexes. b) Use of aniline quenching to monitor enzyme 
reactions61,62 c) Borbas’ caged antenna,63,64 where an enzymatic reaction on an 
appropriate cage (blue circle) generates a coumarin antenna leading to lanthanide(III) 
emission.  
Other reactivity-based probes function by chemical 
modification of a stable lanthanide complex with an integral 
sensitising group. The Nagano group prepared a Tb(III) 
complex, based on DTPA ligand bearing a salicylic acid 
derivative, for monitoring alkaline phosphatase (ALP) activity. 
Enzymatic hydrolysis of a phosphate monoester present on the 
salicylic acid hydroxyl group resulted in a bathochromic shift in 
the absorption spectrum of the chromophore, allowing 
ratiometric analysis of Tb(III) emission intensity upon 
excitation at two different wavelengths.65 The same 
researchers utilised the singlet excited state quenching ability 
of an aniline moiety (by photoinduced electron transfer, PeT) 
on a quinolinone antenna, to detect the activity of a protease 
and N-acetyltransferase (Figure 3b),61,62 monitoring the 
hydrolysis or formation of an amide bond, respectively. When 
the aniline is present, the HOMO of this moiety transfers 
electrons to the singlet excited state of the antenna, 
deactivating it and preventing energy transfer to the 
lanthanide excited state. The corresponding amide has a lower 
energy HOMO, preventing PeT quenching of the antenna, 
promoting sensitisation of Ln(III) luminescence. 
Functionalisation of the aniline moiety with a leucine residue 
allowed continuous monitoring of the activity of a protease, 
microsomal leucine aminopeptidase (LAP), which hydrolyses 
most N-terminal amino acids from peptides, with a preference 
for leucine or alanine.17 In subsequent work, N-
acetyltransferase (NAT) activity was monitored by observing 
the reverse PeT switching process: measuring the switching on 
of Tb(III) emission as the aniline is converted to an acetanilide 
group. This enzyme reaction could be monitored using both 
purified enzyme and in cell lysate.18  
Kikuchi and coworkers originally developed a similar assay for 
protease activity,66 based on a stable Tb(III) complex bearing 
an aniline group that sensitises Tb(III) emission. The 
corresponding Tb(III) complex bearing an amide group was 
weakly luminescent, due to inefficient energy transfer to the 
Tb(III) emissive state. However, upon enzymatic hydrolysis the 
aniline is revealed, switching on luminescence. This aniline 
moiety was functionalised with two short peptides, allowing 
the activity of two different proteases, calpain I and leucine 
aminopeptidase, to be monitored according to the different 
peptide consensus sequences. 
The Gunnlaugsson group have developed an assay using 
glycosylated Tb(III) cyclen complexes to follow glycosidase 
enzyme activity.67 Cleavage of the glycosidic bond in the 
presence an appropriate glycosidase, reveals a phenol antenna 
that increases the intensity of Tb(III) luminescence. This was 
used to detect the activity of β-glucosidase in real-time. 
However, the assay required high (millimolar) concentrations 
of the glycosylated Tb(III) probe, which gave rise to a gradual 
enhancement in luminescence in the absence of enzyme.  
Enzyme activity may be monitored by ratiometric analysis of 
two emission bands of a single Ln(III) complex, or pairs of 
emission bands from two different Ln(III) complexes of a 
common ligand. The Sames group utilised the latter approach 
to monitor esterase activity in real-time, using a ‘cocktail’ of 
1:1 Eu(III)/Tb(III) complexes of a common DTPA ligand, bearing 
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a single carbostyril antenna functionalised with an ethyl ester. 
Enzymatic hydrolysis of the ethyl ester lead to differential 
sensitisation of Tb(III) and Eu(III) luminescence.50 This enabled 
esterase hydrolysis activity to be monitored by measuring the 
intensity ratio of selected Eu(III)/Tb(III) emission bands. 
The Borbas group have used a different approach, creating a 
Ln(III) complex with a ‘caged’ antenna precursor.63,64 The cage 
masks a phenolic OH group, which when revealed triggers an 
intramolecular cyclisation to generate a coumarin antenna, 
capable of sensitising Eu(III) or Tb(III) luminescence (Figure 3c). 
Variations in the nature of the cage moiety allowed the activity 
of different enzymes to be monitored, as well as the detection 
of various analytes (e.g. fluoride, H2O2). Functionalisation of a 
common ligand with cages bearing galactose, glucose, 
mannose and phosphate allowed β-galactosidase, β-
glucosidase, α-mannosidase and phosphatase activity to be 
monitored. Notably, the detection of β-galactosidase activity 
was reported in living lacZ bacteria.63 
 
 Figure 4. Lanthanide(III) labelled antibodies for monitoring enzyme reactions. a) 
Heterogeneous assay on a solid support. The enzymatic product is recognised by an 
antibody on a solid support, while the substrate is washed away. The antibody-antigen 
construct is recognised by a Eu(III) labelled antibody, and the excess washed away. 
Addition of an ‘enhancement solution’ dissociates the Eu(III) ion from the antibody, to 
give a luminescent complex which is detected. b) Homogeneous assay. A luminescent, 
Eu(III) labelled antibody recognises the fluorescently labelled enzymatic product, but 
not the substrate. This allows FRET to occur between the Eu(III) complex donor to the 
fluorescent label. 
Lanthanide labelled biomolecules 
Labelled antibodies 
The use of lanthanide(III) labelled antibodies has been well 
developed,27,52,60,68 and utilised in several commercial enzyme 
assays. These assays can be divided into two classes: 
heterogeneous and homogeneous. Heterogeneous assays 
(Figure 4a) rely on the recognition of the enzyme reaction 
mixture by an antibody bound to a solid support, as 
exemplified by Perkin Elmer’s DELFIA® (dissociation enhanced 
lanthanide fluorescence immunoassay).27,60,69–71 The antibody-
antigen construct is then recognised by a Ln(III) labelled 
antibody. Addition of an enhancement solution dissociates the 
lanthanide(III) ion from the antibody and generates a 
luminescent Ln(III) species, usually by providing a coordinating 
β-diketonate antenna. This assay methodology allows 
detection of low concentrations of enzyme reaction 
substrate/product (less than 10-17 mol/well) with high signal to 
noise, but is not particularly high-throughput, as it requires 
multiple washing steps. The homogeneous assays (Figure 4b) 
operate on a similar principle,26,72–74 however the detection 
strategy is different. Generally, the enzyme substrate and 
product are labelled with an organic fluorophore, either by 
recognition by a labelled antibody (cisbio’s HTRF®) or by direct 
labelling of the substrate peptide (Perkin Elmer’s Lance® or 
ThermoFisher Scientific’s Lanthascreen™). The enzymatic 
product is then recognised by a Ln(III)-labelled antibody, which 
acts as a FRET donor to the organic fluorophore, allowing time-
resolved FRET to be observed. Other homogenous assays rely 
on the competition for binding between the enzymatic 
product or substrate and a fluorescently labelled analogue, 
exemplified by Thermofisher Scientific’s Adapta® and another 
version of cisbio’s HTRF® assays. These homogeneous assays 
are much more high-throughput relative to the heterogeneous 
assays, and provide high sensitivity; however, they are still 
end-point assays, which precludes their use for monitoring 
enzymatic reactions in real time. 
Adaptations to these antibody-based assays have been made 
to obviate the need for the labelled antibody. To this end, an 
assay for Cds1/Chk2 kinase activity was developed,75 following 
the same groups use of a more conventional HTRF assay.76 This 
assay relies on the chemical conversion of the enzymatically 
generated phosphoserine residue on a biotinylated peptide to 
a Cyanin 5 luminescence acceptor, followed by addition of an 
Eu(III)-cryptate functionalised streptavidin bead to capture the 
peptide. The ratio of Eu(III) emission to Cy5 emission can be 
used to signal the progress of the enzyme reaction.  
 
Terbium(III) ion binding to peptide and proteins 
The incorporation of lanthanide(III) ions into peptides and 
proteins is an active field of research, facilitating spectroscopic 
characterisation of protein structure using photophysical, NMR 
and X-ray crystallographic techniques.15,77–80 The first reports 
of incorporation of lanthanide(III) ions into proteins were 
based on endogenous calcium(II) binding sites, replacing Ca(II) 
ions with Tb(III) ions, which have a similar ionic radius and 
oxophilicity.81–83 Tb(III) ions are advantageous in this regard as 
tryptophan residues within the protein can act as suitable 
antennae to generate emissive species. This methodology was 
used to perform some basic enzyme studies, including the 
study of metal ion binding to trypsin,83 α-chymotrypsin,83 and 
heparinase,84 and inhibitor binding to elastase.82 More 
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recently, Hamachi and coworkers have used a known Tb(III) 
binding site along with fluorescein-labelling in the mannose 
binding protein, Concanavalin A, to develop a FRET assay for 
tracking the enzymatic hydrolysis of mannose from a 
glycoprotein by α-mannosidase.85 
The Imperiali group have worked extensively on the 
development of lanthanide binding tags (LBTs),15,45,86–92 
comprising between 17 and 23 amino acids which can 
coordinate to lanthanide(III) ions, predominantly via aspartate 
and glutamate residues. Typically, the peptide contains a 
tryptophan residue to sensitise a coordinated Tb(III) ion. LBTs 
can be incorporated into proteins using standard recombinant 
protein techniques, or synthesised as peptides and tagged to 
the protein of interest via cysteine (Cys) residues. Initially 
these LBTs were based on a calcium(II) binding loop of the EF-
hand, but split-and-pool peptide synthesis techniques lead to 
the development of novel peptides with high affinities for 
terbium(III),87,93 with KD values measured between 9 μM and 
220 nM in buffered aqueous solution. Further developments 
involved the use of non-natural amino acids bearing acridone 
or carbostyril chromophores, allowing sensitisation of a 
coordinated Eu(III) ion.86 LBTs have been attached to several 
different proteins including ubiquitin88 and interleukin-1β,45 
enabling optical visualisation of proteins both in vitro and in 
cellulo, as well as aiding in NMR and X-ray crystallographic 
studies. Using a similar approach to LBTs, a variation on a zinc 
finger was developed, termed a ‘lanthanide finger’, which 
incorporates a ββα tertiary structure, using four carboxylate 
(Asp2Glu2) residues to bind a Tb(III) ion, and a tryptophan 
residue for sensitisation of luminescence.94 Stabilisation of the 
peptide secondary structure was found to increase Ln(III) 
binding affinity. 
Lanthanide binding tags have been utilised to monitor 
protease activity.92 A genetically encoded protein consisting of 
a green fluorescent protein (GFP) and an LBT, separated by a 
linker containing cleavage sites for the proteases caspase and 
trypsin (Figure 5a). When the protein construct is intact, long-
lived FRET occurs between the Tb(III) donor (present in the 
LBT) and the proximate GFP acceptor. Upon proteolytic 
cleavage of the linker, the LBT and GFP components are no 
longer in close proximity and FRET does not occur, hence the 
long-lived fluorescence of GFP is not detected. The utility of 
this assay was demonstrated by obtaining caspase-3 enzyme 
dose response curves and inhibitor dose response curves.  
 
Using phosphorylation to affect Ln(III) ion peptide binding  
The reversible phosphorylation of serine (Ser), threonine (Thr) 
and tyrosine (Tyr) residues on proteins regulates a wide range 
of signal transduction events, directing cellular processes 
including proliferation, trafficking and adhesion.95,96 
Misregulation of the phosphorylation and dephosphorylaiton 
process, catalysed by kinases and phosphatases respectively, 
has been implicated in various diseases including cancer. 
Therefore, the need for simple, precise methods to monitor 
reversible phosphorylation of peptides and proteins is well 
recognised in drug discovery.  
The phosphorylation state of a peptide or protein can have a 
profound effect on its ability to coordinate lanthanide ions. 
This was first shown using a peptide fragment of α-
synuclein,97,98 containing two phosphorylation sites (Tyr125 
and Ser129) with flanking Glu and Asp residues. 
Phosphorylation of either the tyrosine or serine residue 
increased the Tb(III) binding affinity; a KD value of 300 nM was 
measured for the 1:1 complex of the peptide bearing 
phosphorylated Tyr125 residue.  
 
Figure 5. Use of lanthanide binding tags (LBTs) for monitoring enzyme reactions.  a) 
Detection of protease activity by FRET from the LBT to GFP. Upon proteolytic cleavage 
at the protease recognition sequence, the LBT and GFP are no longer part of the same 
construct so FRET does not occur, and Tb(III) emission is observed92. b) Protein kinase 
inducible domain,99 phosphorylation of an amino acid (X) generates a Tb(III) ion 
chelating peptide, creating a luminescent complex. In this case a tryptophan residue, or 
phosphotyrosine residue, acts as the lanthanide antenna. 
The Zondlo group used a variation of the lanthanide binding 
tags to monitor kinase activity,99 wherein the phosphorylation 
of a serine residue modulates the binding affinity of a Tb(III) 
ion (Figure 5b). It was found that a Glu residue, important for 
structure and Tb(III) ion binding within the LBT, could be 
replaced with a phosphoserine residue to create an emissive 
1:1 complex with Tb(III), whereas the peptide bearing a non-
phosphorylated serine was unable to bind a Tb(III) ion, hence 
no Tb(III) centred emission was observed. Upon 
phosphorylation of the peptide, coordination of the Tb(III) ion, 
in close proximity to a Trp antenna, resulted in sensitised 
Tb(III) luminescence. This was termed a ‘protein kinase-
inducible domain’ (pKID). Such domains were designed to 
contain minimal consensus sequences for different kinases, 
including protein kinase A (PKA), protein kinase C (PKC) and 
mitogen-activated protein kinase (MAPK). The end-point 
phosphorylation was detected for PKA. In subsequent work, 
this approach was developed for use with Tyr/pTyr residues, 
allowing the action of Abl kinase and YOP (a tyrosine 
phosphatase) to be detected.100 
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Other phosphotyrosine (pTyr) containing peptides have been 
developed that bind to Tb(III), using the pTyr residue to 
sensitise Tb(III) emission.101–105 An acidic peptide was used, 
containing a central tyrosine residue, which acts as a specific 
substrate for spleen tyrosine kinase (Syk).101,106 The 
phosphorylated peptide was found to bind Tb(III) ions 5 times 
more strongly than to the non-phosphorylated analogue, and 
with a substantial increase in emission intensity. This 
difference was used to monitor phosphorylation by Syk, and to 
determine the IC50 of the known Syk inhibitor, piceatannol. 
Using the same strategy, a peptide substrate for anaplastic 
lymphoma kinase (ALK) was prepared, whose phosphorylation 
could be monitored by measuring the increase in emission 
intensity upon Tb(III) ion binding. 103 This assay was developed 
further to monitor two enzyme reactions simultaneously, using 
FRET based techniques.102 Labelling of the Syk peptide 
substrate with 5-carboxyfluorescein, and a phosphorylation-
dependent Tb(III) binding substrate of Lyn with cyanine 5, the 
emission of the two fluorophores could be detected 
separately. Using time-resolved FRET from the Tb(III) ion 
donor, the fluorescence emission of both organic fluorophores 
was dependent on phosphorylation and was therefore used to 
monitor the activity of the two enzymes independently, in the 
same assay. Tagging the phosphorylation-dependent Tb(III) ion 
binding peptides with biotin,104 allowed its strong interaction 
with streptavidin functionalised quantum dots, which were 
also used for time-resolved FRET signalling of the activity of Src 
and Syk kinases.  
However, as is the case for all of these assays, the presence of 
free Tb(III) ions can be a considerable drawback, because these 
ions can interact with nucleotides or nucleic acids present in 
the sample, resulting in unwanted background emission .107,108  
 
Attaching lanthanide complexes to peptides and proteins 
Other methods for labelling proteins and peptides with 
lanthanide(III) ions involve covalent attachment of a stable 
lanthanide(III) complex to amino acid residues within 
proteins,109–112 or to incorporate non-natural, chelating amino 
acids into peptides, often based on aminodiacetate ligands.14 
Similar strategies using conventional fluorophores are 
common practice in the design of many biological assays for 
ligand binding and enzyme activity.113–115 Lanthanide-based 
peptide probes have been used most extensively for 
monitoring kinase and phosphatase reactions.17 The use of 
peptide-based biosensors for phosphorylation can be 
advantageous, as the sensing of phosphorylation state can, in 
certain cases, occur in the presence of other phosphate 
species, such as ATP and ADP.17 
Initial studies using a simple lanthanide ligand attached to a serine-
tryptophan or phosphoserine-tryptophan dipeptide,116 using the 
tryptophan as an antenna, found that terbium(III) emission was 
increased with the non-phosphorylated ligand, compared to the 
phosphorylated ligand. This was attributed to a switch between a 
monomer and dimer with the phosphorylated and non-
phosphorylated peptide, respectively. This change in emission was 
used to follow the enzymatic dephosphorylation of the 
phosphorylated peptide, using alkaline phosphatase. Further 
development involved modification of the chelating ligand, 
introducing a non-natural quinolone antenna and a bulky isoleucine 
residue between the antenna and the phosphorylated amino acid 
(now tyrosine), and extending the N-terminus of the peptide. This 
allowed a Tb(III) and Eu(III) labelled peptide to be created, which 
displayed increased luminescence emission on phosphorylation 
(Figure 6a).117 This was used to monitor the conversion between 
the phosphorylated and non-phosphorylated peptides using the 
tyrosine phosphatase PTP1B or the tyrosine kinases ab1 and Src. 
 
Figure 6. Use of lanthanide(III) complexes attached to peptides to monitor enzyme 
reactions. a) Monitoring tyrosine kinase and phosphatase activity on a short 
pentapeptide. Upon phosphorylation of a tyrosine residue, the peptide becomes a 
lanthanide chelator, generating a luminescent species.117 b) An Eu(III) complex attached 
to an aspartic acid residue in a peptide coordinates to a phosphoserine residue. On 
dephosphorylation by a phosphatase, the Eu(III) complex coordinates to a β-diketonate 
antenna to generate an emissive Eu(III) complex. Phosphorylation of the serine residue 
by a kinase displaces the β-diketonate antenna, switching off Eu(III) luminescence.118 c) 
Peptide labelled on a cysteine residue with a Tb(III) complex used to follow a kinase 
reaction. Phosphorylation of a serine residue on the peptide substrate results in 
interaction of the peptide with the recognition unit, bringing a tryptophan antenna in 
close proximity to the Tb(III) complex, generating an emissive species.119 
More recently, lanthanide(III) complexes with high kinetic and 
thermodynamic stability have been conjugated to peptides to 
monitor kinase and phosphatase activity. The luminescence of 
the attached complex is affected by the phosphorylation state 
of a proximate serine or tyrosine residue within the peptide.118 
A lanthanide complex (Ln = Eu, Tb), based on a DO3A 
propylamino ligand, was attached to an Asp residue of a resin-
bound peptide using orthogonal protecting group chemistry. 
Coordination of a proximate phosphoserine residue caused 
competitive displacement of a β-diketonate antenna from the 
Eu(III) complex, resulting in a decrease in Eu(III) intensity 
(Figure 6b). Such ‘switching off’ of luminescence was used to 
monitor the PKCα-catalysed phosphorylation of the peptide, 
determining Michaelis-Menten parameters for the enzyme. 
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Conversely, the alkaline phosphatase catalysed 
dephosphorylation reaction could be monitored by observing 
an increase in Eu(III) emission intensity upon preferential 
binding to the β-diketonate antenna. More recently, an assay 
for CDK4/cyclin D kinase activity was developed (Figure 6c),119 
capable of operating in melanoma cell extracts and reporting 
on CDK4 inhibition. The Tb(III)-based biosensor comprises a 
CDK4 substrate sequence attached to a recognition domain for 
the phosphorylated peptide. The DO3A Tb(III) complex was 
conjugated to the peptide substrate via a cysteine residue 
using maleimide chemistry, while a tryptophan antenna was 
positioned in the recognition domain. In the unphosphorylated 
state, the recognition peptide is distant from the substrate 
peptide, so inefficient sensitisation of Tb(III) emission occurs. 
However, upon phosphorylation, the recognition domain binds 
to the substrate peptide, increasing proximity of the 
tryptophan residue and the efficiency of Tb(III) sensitised 
emission. 
The Komiyama group prepared a binuclear Tb(III) complex, 
based on two DOTAM (tetramide) ligands with an alkyne 
functionalised ethylene linker, for conjugation to an optimised 
substrate for protein tyrosine kinase Abl, via click chemistry.120 
Intramolecular coordination of a phosphotyrosine residue to 
the bis-Tb(III) complex enabled energy transfer from the 
excited pTyr group to the Tb(III) centre. This biosensor and its 
derivatives, based on other peptide sequences, were used to 
monitor the activity of Abl and Src, deriving Michaelis-Menten 
parameters and calculating IC50 values for known inhibitors 
(e.g. dasatanib). 
Recently, the Härmä group have developed a quenching 
resonance energy transfer (QRET) assay for monitoring the 
activity of different enzymes, including kinases, phosphatases 
and deacetylases.121 The assay is based on disruption of a 
leucine zipper peptide pair interaction. An Eu(III)-chelate was 
attached to the N-terminus of a ‘detection peptide’, which 
forms a stable dimer with an enzyme substrate peptide. The 
peptide pair is luminescent, as the Eu(III) chelate is protected 
from quencher molecules present in solution. Enzymatic 
modification of the peptide substrate (e.g. phosphorylation) 
causes dissociation of the peptide pair and exposure to 
quencher molecules, decreasing the Eu(III) emission intensity. 
The peptide pair re-associates when the phosphate group is 
cleaved from the substrate, allowing both kinase and 
phosphatase activity to be monitored, demonstrated using 
PKA and PTP1B, respectively. This approach eliminates the 
need to chemically modify the substrate peptide, providing a 
potentially versatile platform for monitoring different enzyme 
catalysed post-translational modifications.  
 
Lanthanide-labelled small molecules and anions 
Various small molecules involved in enzyme reactions may also 
be labelled with lanthanide(III) complexes. The Härmä group 
have used terbium(III) labelled phosphoanions (e.g. GTP)122–128 
in QRET assays for various applications, including ligand-
receptor binding and monitoring GTPase reactions. The QRET 
assay relies upon binding of the labelled small molecule or 
anion to its receptor, masking the Ln(III) ion from quenching 
molecules in solution, switching on its luminescence (Figure 
7a). Dissociation of the labelled species from its receptor 
causes quenching of Ln(III) emission intensity. 
 
Figure 7. Using labelled GTP to monitor enzyme reactions. a) QRET strategy for 
monitoring GTP binding to a GTPase. When unbound to a protein the Tb(III) labelled 
GTP is surrounded by quencher molecules which quench the Tb(III) luminescence. On 
binding of the Tb(III) labelled GTP to a protein (promoted by a GEF), the Tb(III) is 
masked from the quencher molecules in solution and becomes emissive.128 b) Structure 
of Tb(III) labelled GTP.129 
Vuojola and coworkers first synthesised a Tb(III) and Eu(III) 
labelled GTP (Tb(III)-GTP shown in Figure 7b), attached to the 
ribose moiety via a thiourea linkage, to study GTPase activity 
using a guanine nucleotide exchange assay.129 GTPases behave 
as molecular switches, cycling between a GDP bound (inactive) 
and GTP bound (active) conformation in a controlled manner. 
GTP/GDP exchange is promoted by guanine nucleotide 
exchange factors (GEF), whereas the GTPase activity is 
promoted by a GTPase-activating proteins (GAP). Binding of 
GTP to the GTPase Rab21 was monitored using the Ln(III)-
labelled GTP, by following exchange of the guanine nucleotide 
on a GFP or YFP labelled Rab21, using FRET. When guanine 
nucleotide exchange was occurring, the Ln(III)-GTP (FRET 
donor) competes with GTP for interaction with Rab21. 
Excitation of the bound Ln(III)-donor allows energy transfer to 
the proximal GFP or YFP acceptor. When nucleotide exchange 
was not occurring, no FRET induced GFP or YFP emission was 
observed.  
The same Tb(III)-labelled GTP was utilised by the Härmä group 
to monitor guanine nucleotide exchange of the small GTPase 
Ras, using a QRET strategy.123 This approach obviates the need 
for a GFP or YFP fused protein, but additionally requires the 
use of quencher molecules. In subsequent work, a 
heterogeneous assay to study GTP hydrolysis (Ras 
deactivation) was developed.130 The assay utilised an antibody 
selective for GTP (over GDP, ATP and CTP) to determine the 
endogenous GTP concentration. An Eu(III) chelate was 
conjugated to streptavidin, which was bound strongly to 
biotin-labelled GTP. This streptavidin-bound GTP competes 
with endogenous GTP for interaction with the surface-bound 
antibody. After washing, the binding of the Eu(III)-labelled 
biotin-streptavidin species was reported by time-resolved 
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luminescence emission, providing an indirect measure of 
endogenous GTP and hence the extent of GTP hydrolysis. 
Using this approach, initial studies of inhibitors of the protein-
protein interactions necessary for Ras functioning were 
conducted. Recently, this assay was further developed for use 
in a homogeneous assay,131 using a QRET strategy to provide a 
HTS-compatible platform for GTPase inhibitor/activator 
screening. 
Using discrete responsive lanthanide probes 
Discrete Ln(III) complexes may be used to follow an enzyme 
reaction, by binding reversibly to a substrate or product, 
reporting on the depletion or accumulation of these species by  
a change in luminescence emission or lifetime of the Ln(III) 
complex. The use of discrete lanthanide complexes in enzyme 
assays offer advantages over the labelling of peptides or small 
molecules. Firstly, they enable the use of native enzymes and 
substrates, ensuring that enzyme reaction rates and inhibition 
are not affected by the presence of a bulky label on the 
enzyme or substrate. Secondly, the selective recognition of 
generic small molecules (e.g. nucleoside anions) or motifs in 
peptides could allow general assays to be developed that are 
broadly applicable for studying a range of different enzymes 
using a single probe, as opposed to the need to create a new 
labelled biomolecule for each individual enzyme reaction. 
Thirdly, Ln(III) complexes with high kinetic and thermodynamic 
stability can be designed for use in robust assays, minimising 
potential errors in measurements that may arise due to slow 
dissociation of the Ln(III) ion in solution.  
 
Phosphopeptide recognition using lanthanide complexes 
Discrete lanthanide complexes have been used to detect post-
translational modifications of peptides. For example, the 
Parker group have developed cationic Eu(III) complexes for the 
recognition of phosphorylated amino acid residues,132–135 both 
as free amino acids and in short peptide sequences. Reversible 
binding of phosphorylated Tyr, Ser and Thr residues to the 
Eu(III) metal, lead to modulation of europium(III) emission 
intensity and spectral form, as well as changes in NMR spectra. 
The preferential binding to pTyr over pSer (log Ka values of 4.2 
and 2.7, respectively, in 0.1 M MOPS at pH 7.4) was utilised to 
detect various phosphorylated insulin receptor peptides, 
possessing differing numbers of pTyr residues.133  
The Komiyama group designed a binuclear Tb(III) complex 
which acts as a probe for tyrosine phosphorylation (Figure 
8),136 following the initial use of a mononuclear Tb(III) DOTAM 
complex for sensing phosphotyrosine, both as a free amino 
acid and within a nonapeptide.137 The cationic bis-Tb(III) 
complex binds to a range of phosphate species via 
electrostatic interactions, including phosphorylated 
Ser/Thr/Tyr residues and nucleoside mono- and triphosphate 
anions. However, the probe provides a distinctive ‘switching 
on’ of emission intensity upon binding to pTyr, due to energy 
transfer from the excited phenolic chromophore to the 
proximate Tb(III) centre. This increase in emission intensity 
was used to continuously monitor the Src kinase catalysed 
phosphorylation of a highly negatively charged peptide 
substrate. Using the same anionic substrate, this Tb(III) 
complex was later utilised to monitor different kinases (Fyn 
and EGFR), two protein tyrosine phosphatases and to obtain 
dose response curves for known inhibitors of these enymes.138 
It should be noted that in this strategy, the detection 
sensitivity of the probe diminishes notably when the substrate 
peptides contain positively charged amino residues, which 
repel the Tb(III) complex, suppressing the modest Coulombic 
attraction between the probe and pTyr. Subsequent efforts to 
address this issue involved conjugation of the binuclear Tb(III) 
complex to peptide substrates, allowing intramolecular 
association of the pTyr residue, as described previously.120  
 
Figure 8. A binuclear Tb(III) complex (left), which is able to bind to a phosphotyrosine 
residue on a peptide, which acts as an antenna for Tb(III) sensitisation.136 
Anion and small molecule binding to lanthanide probes 
Significant progress has been made over the last 15 years, in 
the development of lanthanide complexes capable of binding 
and sensing a variety of anions, and small molecules.36,38,48,139–
143 Here, we focus on their application in monitoring enzyme 
reactions. 
A luminescence quenching assay has been developed to 
monitor the enzymatic conversion between the coenzymes 
NAD(P)H  and NAD(P)+.144,145 A short series of stable Tb(III) 
complexes containing an azaxanthone chromophore were 
prepared (including Figure 9a), based on previous design by 
Parker,146 which was shown to be susceptible to dynamic 
quenching by various endogenous anionic reductants (e.g. 
ascorbate, urate). Similarly, NAD(P)H was found to interact 
with the positively charged Tb(III) complexes, dynamically 
quenching their luminescence, whereas NAD(P)+ did not bind 
to an appreciable extent so had little effect on the Tb(III) 
emission intensity. The quenching response observed in the 
presence of NADH was used to monitor the activity of lactate 
dehydrogenase, which catalyzes the reduction of pyruvate to L-
lactate, converting NADH into NAD+ in the process. 
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The Gunnlaugsson group have developed a pH-responsive 
Eu(III) probe for monitoring urease activity (Figure 9b).147 The 
luminescence of the Eu(III) complex is changed from being 
highly emissive to weakly emissive on conversion of urea to 
ammonia and carbon dioxide, due to the change in pH of the 
solution (from pH 6 to pH 8). This ‘switching-off’ of 
luminescence enabled profiling of urease activity, and the 
determination of rate constants and activation energies for the 
enzyme. Impressively, the probe was further developed for use 
in a stable hydrogel matrix, demonstrating the potential for 
incorporation into catheters, for the detection of urinary tract 
infections in the clinic.  
 
 
Figure 9. Lanthanide(III) complexes capable of binding to small molecules. a) Tb(III) 
complex that binds non-covalently to NAD(P)H over NAD(P)+, enabling the activity of 
lactate dehydrogenase to be monitored.144 b) pH responsive Eu(III) probe used to 
monitor urease activity.147 c) Tb(III) probe for sensing of glutathione. Glutathione reacts 
with the maleimide moiety to generate an emissive species. This was used to monitor 
the activity of glutathione reductase.148 
Gunnlaugsson also reported a terbium(III) complex, based on a 
DOTAM derivative functionalised with a maleimide arm, for 
the sensing of thiols (Figure 9c),148 such as glutathione, a key 
cellular antioxidant. The maleimide moiety reacts with thiols to 
generate a luminescent Tb(III) complex, with a ~5-fold increase 
in emission intensity observed on reaction with a thiol. This 
was utilised to monitor the reduction of oxidised (disulfide) 
glutathione by glutathione reductase in the presence of 
NADPH, leading to generation of reduced glutathione, with a 
free thiol group that reacts rapidly with the Tb(III) complex. 
 
Sensing of biological phosphoanions 
Biological phosphoanions represent an important class of 
molecules involved in a variety of cellular processes, including 
energy metabolism, DNA/RNA synthesis and organelle 
transport.149–151 Numerous enzyme reactions rely on the 
conversion between different phosphoanion species, for 
example, kinase reactions convert ATP to ADP, GTPases 
convert GTP to GDP. Therefore, the creation of probes capable 
of molecular recognition and sensing of these different 
species, could enable the development of enzyme assays for a 
range of enzyme classes. 
 
Figure 10. Lanthanide(III) complexes and ligands for sensing biological anions. a) 
Tetracycline, used as an Eu(III) ligand for sensing ATP and monitoring creatine kinase 
and alkaline phosphatase activity152 b) Norfloxacin, used as a Tb(III) ligand for 
monitoring adenylate cyclase and GTPase activity.153,154 c) Eu(III) complex which senses 
ATP and was used to monitor ATPase and apyrase activity.155 d) Tb(III) probe capable of 
sensing (by π-stacking with the adenine base) and discriminating (by charge) ATP, ADP 
and AMP.156 e) Eu(III) complex used in combination with the Tb(III) complex in d) to 
develop a ratiometric PKA assay. 
Eu(III) complexes of the antibiotic tetracycline (Figure 10a) and 
its derivatives have been developed as luminescent probes for 
ATP and phosphate, and utilised for real-time analysis of 
enzyme activity.152–155,157,158 The Schäfferling group showed 
that addition of ATP to a 1:1 mixture of Eu(III)/tetracycline 
caused significant (75%) quenching of Eu(III) emission 
intensity. Using different ratios of Eu(III) ion to tetracycline, 
the activities of creatine kinase (1:1),152 and alkaline 
phosphatase (3:1) were monitored,157 by measuring the 
increase in Eu(III) luminescence as a result of ATP hydrolysis. In 
subsequent work, a 1:1 mixture of Tb(III)/norfloxacin (Figure 
10b) was used to monitor the conversion of ATP to cAMP and 
pyrophosphate (PPi), catalysed by adenylate cyclase.153 A 5-
fold increase in emission intensity was observed on addition of 
ATP, whereas addition of PPi caused a 5-fold decrease in 
emission and cAMP did not induce a spectral response. The 
probe was used to study the effect of the activator calmodulin, 
and to obtain inhibitor dose response curves. This compound 
was also used to monitor the activity of the GTPase Ras.154 In 
the absence of a guanine exchange factor (GEF), Ras has GTP 
or GDP bound, and does not release it, but gradually converts 
GTP to GDP with the release of phosphate. It was found that 
inorganic phosphate quenches the luminescence of a 1:1 
mixture of Tb(III)/norfloxacin by 90%, therefore it could be 
used to monitor the increase in phosphate concentration as 
Ras hydrolyses GTP to GDP.154 Changes in enzyme reaction 
rate at different temperatures were monitored, as well as the 
action of GTPase activating proteins (GAPs). In recent work, 
the same researchers synthesised a pentadentate Eu(III) 
complex with an alkynylpyridine sensitiser (Figure 10c), which 
showed a large (60-fold) enhancement in luminescence upon 
binding to ATP.155 ADP induced a comparatively smaller 27-fold 
enhancement in emission intensity, whereas AMP showed a 
negligible spectral response. However, interference by the 
Mg2+ cofactor caused almost complete loss of sensing 
selectivity between ATP and ADP, due to competitive binding 
of Mg2+ to ATP. Nevertheless, it was possible to use the probe 
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at low ionic strength to monitor the activity of ATPase (ATP to 
ADP) and apyrase (ATP or ADP to AMP) in real-time. 
The Pierre group have developed Ln(III) probes that can 
distinguish ATP and GTP from ADP and GDP respectively.156,159 
Initially, a cyclen-based terbium(III) probe was synthesised 
with an phenanthridine antenna, capable of π-stacking with 
the adenine base of ATP, ADP and AMP (Figure 10d). This 
favourable interaction caused PeT quenching of the excited 
state of the phenanthridine antenna, resulting in a decrease in 
Tb(III) emission.159 Discrimination of the three species was 
achieved by differential electrostatic interactions between the 
positively charged Tb(III) complex and the phosphates of the 
nucleobases. They later used this complex,156 together with a 
similar but overall neutral Eu(III) complex (Figure 10e), to 
develop a ratiometric assay capable of detecting ATP/ADP and 
GTP/GDP ratios, by calibrating the changes in the Tb(III) 
emission bands against the less sensitive bands of the Eu(III) 
analogue. This was used to monitor the activity of protein 
kinase A, by measuring a decrease in the quenching of Tb(III) 
emission over the course of ATP to ADP conversion. 
 
 
Figure 11. Monitoring of enzyme activity using an anion-responsive Eu(III) complex.160 
a) Cationic Eu(III) complex used. b) Cartoon depicting sensing of the conversion of ATP 
to ADP during the PKA-catalysed phosphorylation of a serine containing peptide. 
Emission of the Eu(III) complex is enhanced upon conversion of ATP to ADP over the 
enzyme reaction. c) Variation in emission spectral form of the Eu(III) complex (8 μM) on 
titration of ADP into ATP (1 mM total concentration) in the presence of 3 mM MgCl2. d) 
The linear response observed in the emission intensity ratio, 616/599 nm, on increasing 
ADP concentration. e) Cartoon showing sensing of adjacent phosphotyrosine residues 
using the same Eu(III) complex. 161 
Recently, we have prepared a cationic Eu(III) complex bearing 
two quinoline arms,162 for the discrimination of ATP and ADP 
(Figure 11).160 The Eu(III) complex binds reversibly to ATP and 
ADP, displacing the coordinated water molecule and producing 
distinctive changes in emission intensity and spectral form. 
Discrimination between ATP and ADP was enhanced in the 
presence of magnesium(II) ions, at concentrations used in 
conventional kinase assays, a factor which can often interfere 
with ATP/ADP discrimination.155 This enabled the change in the 
ratio of ATP/ADP to be monitored continuously during a PKA 
catalysed phosphorylation reaction, by measuring a 
ratiometric change in Eu(III) emission intensity (Figure 11c and 
d). The phosphorylation reaction was monitored at different 
enzyme concentrations, showing linearity between the 
concentration of enzyme and the initial rates of reaction. The 
Eu(III) probe was compatible with different biologically 
relevant conditions, including changes in pH, addition of NaCl, 
DTT and DMSO, and is well suited for screening of inhibitors (or 
activators) of kinase activity, as demonstrated by monitoring 
the effect of staurosporine on the activity of PKA. The ability to 
function in a wide range of conditions is particularly valuable in 
the design of general assays that can be used for classes of 
enzymes. In subsequent work, we demonstrated the ability of 
this Eu(III) complex to detect adjacent phosphotyrosine 
residues on pentapeptide sequences (Figure 11e), sensing the 
pYpY motif over YpY, YY, pSpS and pTpT motifs at similar 
concentrations.161 This enabled the acid phosphatase catalysed 
dephosphorylation of the peptide ApYpYAA to be monitored in 
real-time. 
Conclusions 
Monitoring enzyme reactions is of great importance for 
understanding enzyme mechanisms and inhibition. The 
advantages of using luminescent lanthanide complexes to 
probe enzyme activity have been demonstrated in a variety of 
ways. The unique photophysical properties of lanthanide ions 
provide advantages over conventional organic fluorophores, 
including large separations between the absorption and 
emission bands, line-like emission spectra, and long 
luminescence lifetimes, which permit time-resolved 
luminescence detection techniques.22 The existence of 
commercial assays, in the form of lanthanide-labelled 
antibodies, means that appropriate instrumentation already 
exists for the development of new lanthanide-based enzyme 
assays for use in high-throughput formats. 
Reactivity-based probes have been devised to report on a 
variety of enzyme catalysed reactions,12 either by generating a 
lanthanide chelating antenna or modulating the photophysical 
properties of an attached antenna. Monitoring enzyme 
reactions in this manner does not allow for the use of native 
enzyme substrates and requires new lanthanide probes or 
ligand precursors to be synthesised for each enzyme of 
interest. However, with the design and synthesis of enzyme-
specific, cell permeable lanthanide probes it should be possible 
to monitor enzyme activity in real-time within cells. Indeed, 
some initial success in this regard has been achieved, detecting 
the activity at β-galactosidase in lacZ bacteria.63 This is a 
potentially powerful tool that several alternative types of 
enzyme assays would not be capable of performing, and is 
certainly a field to be pursued further. 
Lanthanide labelled biomolecules (e.g. antibodies) have shown 
great utility as end-point assays for enzyme reactions in vitro, 
with several commercial assays already existing based on 
these techniques. The recognition of the enzymatic products 
by lanthanide labelled antibodies allows for the progress of the 
enzyme reaction to be determined. The development of these 
assays into commercial products shows the reliability and 
practicability of this approach, and has lead to the 
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development of lanthanide-applicable instrumentation for 
high-throughput screening, a factor that will facilitate further 
advances in this area. The development of new antibodies, and 
Ln(III) labelled derivatives, for an increasing number of 
enzymatic products will allow for increasingly specific enzyme 
assays to be developed. 
The labelling of other proteins and peptides can allow 
monitoring of enzyme reactions in real-time, and permits the 
use of low concentrations of reagents. The labelling of 
peptides with conventional organic fluorophores is common to 
many biological assays,7,113,115,163 including for ligand binding, 
and this is being extended readily to exploit the many 
advantages of luminescent lanthanide complexes.14,15,109,118 
Care must be taken in selecting the location and size of the 
attached label, to ensure minimal perturbation of the enzyme 
reaction or inhibitor binding. However, given the widespread 
use of fluorescently labelled peptides and proteins, this is 
unlikely to be seen as a major stumbling block to the adoption 
of this technology. 
The use of discrete lanthanide complexes to monitor enzyme 
reactions is a progressing field, which have already shown 
potential for detecting peptide modifications (e.g. 
phosphorylation/dephosphorylation),136,161 and monitoring the 
formation/depletion of biological anions.160 Importantly, the 
use of discrete lanthanide probes enables the use of native 
enzymes and substrates, and allows the reaction to be 
monitored in real-time. This approach offers the potential to 
develop highly versatile assays that can be applied to whole 
classes of enzymes, by sensing common post-translational 
modifications or the conversion between common biological 
anions or molecules. For example, a probe that can accurately 
signal the phosphorylation of an amino acid, or the conversion 
of ATP to ADP, enables a general assay for kinases to be 
developed, which is not limited to a particular peptide/protein 
substrate or enzyme. While the development of such assays is 
in its infancy, opportunities are available to create robust, 
accurate and high-throughput assays that allow the screening 
of enzyme activity, selectivity and inhibitors. Further advances 
in lanthanide-based enzyme assay development are expected 
in the near future, which may provide attractive alternatives to 
existing commercial assay formats, thus facilitating drug 
discovery.   
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